Drugs / Obrixtamig
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT05963867 | Aug 2024 → Aug 2026 overdue | small cell lung carcinoma | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 1 | NCT06077500 | Feb 2024 → Mar 2027 expected | small cell lung carcinoma | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05990738 | Feb 2024 → Mar 2027 expected | small cell lung carcinoma | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05916313 | Jan 2024 → Aug 2027 expected | glioma | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 1 | NCT06132113 | Jan 2024 → Oct 2027 expected | neuroendocrine neoplasm | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05879978 | Jun 2023 → Jun 2025 overdue | small cell lung carcinoma | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04429087 | Jul 2020 → Aug 2026 overdue | neuroendocrine carcinoma | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07707895 | Oct 2026 → Apr 2030 expected | pulmonary large cell neuroendocrine carcinoma, small cell lung carcinoma | Boehringer Ingelheim | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07843940 | Oct 2026 → Apr 2030 expected | small cell lung carcinoma | Boehringer Ingelheim | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07561645 | Jul 2026 → Apr 2032 expected | pulmonary large cell neuroendocrine carcinoma | Technical University Dresden | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05882058 | Oct 2023 → Sep 2027 expected | small cell lung carcinoma | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07544654 | Jul 2026 → Dec 2029 expected | neuroendocrine carcinoma | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 3 | NCT07472517 | Nov 2025 → Sep 2028 expected | small cell lung carcinoma | Boehringer Ingelheim | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-05-22 | Boehringer Ingelheim | Results Boehringer Ingelheim Showcases Bold Vision for the Future of Cancer Care at ASCO 2025 prnewswire.com ↗
Findings from this study, including a 40% objective response rate, underscore the potential of obrixtamig to produce an effective and durable response in patients with high DLL3 expression, and offer a targeted approach to treating this cancer. |
| 2023-11-29 | Oxford BioTherapeutics Ltd | Regulatory Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung oxfordbiotherapeutics.com ↗ |
All press releases naming this drug 3 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Obrixtamig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07707895 ↗ |
| Known as | BI 764532 | “A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine...” NCT05879978 ↗7“DLL3xCD3 Bispecific T-cell Engager Obrixtamig (BI 764532)” NCT07561645 ↗ |
| Modality | Other / unclassified | “BI 764532 is an antibody-like molecule (DLL3/CD3 bispecific)” NCT05882058 ↗ |
| Route | Other | “Administered by Parenteral Route” NCT04429087 ↗ |
| Target | DLL3 | “a DLL3-targeting T Cell Engager” NCT05882058 ↗ |